Vermont Clinical Trials

A listing of Vermont clinical trials actively recruiting patient volunteers.

Situated in the northeast, Vermont is the only state in New England that doesn't border the Atlantic Ocean. It sits just behind Rhode Island as the second least populated U.S. state overall, known for its dairy farming and forestry. Burlington, Stowe, and Montpelier are some of the top cities, with the latter also serving as the state capital – though Burlington, the biggest, has only about 43,000 residents. Vermont truly stands out as a leader in healthcare innovation despite its modest size. The University of Vermont Medical Center, which has about 6,400 employees, is the largest employer in the entire state.

Search by Name
Search
Filter by Condition
251 trials found

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

NCT04059484

Primary Objective: To determine whether amcenestrant per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer Secondary Objectives: To compare the overall survival in the 2 treatment arms To assess the objective response rate in the 2 treatment arms To evaluate the disease control rate in the 2 treatment arms To evaluate the clinical benefit rate in the 2 treatme ...

Conditions: Breast Cancer Metastatic

Pragmatic RCT of SBIRT-PM

NCT04062214

Veterans seeking compensation for musculoskeletal (MSD) conditions often develop chronic pain and are at high risk for substance misuse. The Investigators propose to test the effectiveness and cost-effectiveness of Screening, Brief Intervention and Referral to Treatment for Pain Management (SBIRT-PM), designed to reduce pain and reduce risky substance use, in part by helping Veterans get comprehensive pain treatment. The study will involve clinicians at a single site contacting Veterans througho ...

Conditions: Substance Use Disorders, Pain
Phase: Not Applicable

Novel Arm Restraint For Critically Ill Patients To Reduce Immobility, Sedation, Agitation and Cognitive Impairment

NCT04067622

This study evaluates a novel arm restraint compared with traditional soft wrist restraints in older critically ill patients. The primary outcome is upper extremity mobility measured by actigraphy, and secondary outcomes include sedation, agitation, satisfaction, and acceptability.

Conditions: Acute Respiratory Failure, Encephalopathy, ARDS, Sepsis, Critical Illness
Phase: Not Applicable

Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)

NCT04069312

A multi-center, randomized, 36-month, parallel- group, non-inferiority, phase III study to compare the effectiveness of roflumilast (Daliresp, 500 mcg quaque die (QD) or alternate regimen) therapy versus azithromycin (250 mg QD, 500 mg QD three times per week, or alternate regimen) to prevent hospitalization or death in a patients at high risk for COPD exacerbations.

Conditions: Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis

Cooking as a Health Behavior in College Students

NCT04084028

Students who live off campus at the University of Vermont will be recruited to participate in the study which will begin in Fall 2019 and run through May 2020. The intervention is a randomized-controlled trial where students will be randomized into one of four conditions: 1) active cooking classes followed by meal kits and recipes, 2) Active cooking classes followed by no further instruction, 3) Demonstration classes followed by meal kits and recipes, or 4) Demonstration classes followed by no f ...

Conditions: Diet, Healthy

Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders

NCT04090879

While the prevalence of smoking in the United States general population has declined over the past 50 years, there has been little to no decline among people with mental health conditions. Affective Disorders (ADs) are the most common mental health conditions in the US, and over 40% of people with ADs are current smokers. A national policy of reducing the nicotine content of cigarettes has the potential to reduce tobacco use, dependence, and related adverse health outcomes. Controlled trials in ...

Conditions: Tobacco Use Disorder

Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder

NCT04092101

Prevalence of smoking among individuals with opioid use disorder (OUD) is six-fold that of the general US adult population. The mortality rate of opioid-dependent smokers is four times that of opioid-dependent nonsmokers, and their response to smoking cessation interventions is notoriously poor. A national policy of reducing the nicotine content of cigarettes has the potential to be an effective method of reducing tobacco use prevalence, dependence, and related adverse health outcomes. Controlle ...

Conditions: Tobacco Use Disorder

Low Nicotine Content Cigarettes in Vulnerable Populations: Women of Reproductive Age

NCT04092387

Despite marked reductions in cigarette smoking in the general population, smoking rates among economically disadvantaged women have increased. Smoking among women of reproductive age is a particular concern because in addition to the usual health risks, there are additional risks should they become pregnant. A national nicotine reduction policy for cigarettes has considerable potential to reduce tobacco use, dependence, and improve health in these smokers. Controlled trials in general population ...

Conditions: Tobacco Use Disorder

Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

NCT04094688

This phase III trial studies how well vitamin D3 given with standard chemotherapy and bevacizumab works in treating patients with colorectal cancer that has spread to other parts of the body. Vitamin D3 helps the body use calcium and phosphorus to make strong bones and teeth. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, oxaliplatin, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells by killing the cells, by stopping them from dividing, ...

Conditions: Colorectal Adenocarcinoma

Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease

NCT04102579

This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine to treat chorea in subjects with Huntington disease.

Conditions: Chorea, Huntington

Prolonged Exposure Therapy for PTSD and Opioid Use Disorder

NCT04104022

Among patients with opioid use disorder (OUD), 90% report lifetime trauma exposure and 33% meet criteria for posttraumatic stress disorder (PTSD). The co-occurrence of OUD and PTSD is associated with worse mental health and opioid agonist treatment (OAT) outcomes relative to either diagnosis alone. Prolonged exposure therapy (PET) is an efficacious cognitive-behavioral treatment for reducing PTSD severity. Although preliminary findings indicate that PET may reduce PTSD symptom severity among pat ...

Conditions: Post Traumatic Stress Disorder, Opioid-use Disorder
Phase: Not Applicable

Cholinergic Health After Menopause (CHAMP)

NCT04129060

Women are at increased risk for Alzheimer's disease (AD). Notably at menopause, some women experience a change in cognition. However, not all women experience negative effects of menopause on cognition. The cognitive changes that occur at menopause have not yet been connected to late life risk for pathological aging including AD. Thus, understanding the neurobiological factors related to individual differences in cognition at menopause is critical for understanding normal cognitive aging and for ...

Conditions: Postmenopausal Symptoms, Aging, Alzheimer Disease
Phase: Early Phase 1